SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-203128"
 

Search: onr:"swepub:oai:DiVA.org:liu-203128" > Hidden in plain sig...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Roncolato, FeliciaUniv Sydney, Australia; Western Sydney Univ, Australia; Campbelltown Hosp, Australia (author)

Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer

  • Article/chapterEnglish2024

Publisher, publication year, extent ...

  • ACADEMIC PRESS INC ELSEVIER SCIENCE,2024
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-203128
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-203128URI
  • https://doi.org/10.1016/j.ygyno.2024.02.025DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|NHMRC [1063012, 570893]; Target Ovarian Cancer [UCL-P001AL]; Cancer Research UK and UCL Cancer Trials Centre [C444/A15953]; Australian Government through Cancer Australia; Department of Health
  • Objective. To describe the baseline symptom burden(SB) experienced by patients(pts) with recurrent ovarian cancer(ROC) prior and associations with progression free survival (PFS) and overall survival (OS). Methods. We analysed baseline SB reported by pts. with platinum resistant/refractory ROC (PRR-ROC) or potentially-platinum sensitive ROC receiving their third or greater line of chemotherapy (PPS-ROC >= 3) enrolled in the Gynecologic Cancer InterGroup - Symptom Benefit Study (GCIG-SBS) using the Measure of Ovarian Symptoms and Treatment concerns (MOST). The severity of baseline symptoms was correlated with PFS and OS. Results. The 948 pts. reported substantial baseline SB. Almost 80% reported mild to severe pain, and 75% abdominal symptoms. Shortness of breath was reported by 60% and 90% reported fatigue. About 50% reported moderate to severe anxiety, and 35% moderate to severe depression. Most (89%) reported 1 or more symptoms as moderate or severe, 59% scored 6 or more symptoms moderate or severe, and 46% scored 9 or more symptoms as moderate or severe. Higher SB was associated with significantly shortened PFS and OS; five symptoms had OS hazard ratios larger than 2 for both moderate and severe symptom cut-offs (trouble eating, vomiting, indigestion, loss of appetite, and nausea; p < 0.001). Conclusion. Pts with ROC reported high SB prior to starting palliative chemotherapy, similar among PRR-ROC and PPS-ROC >= 3. High SB was strongly associated with early progression and death. SB should be actively managed and used to stratify patients in clinical trials. Clinical trials should measure and report symptom burden and the impact of treatment on symptom control. (c) 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • King, Madeleine T.Univ Sydney, Australia (author)
  • O'Connell, Rachel L.Univ Sydney, Australia (author)
  • Lee, Yeh ChenUniv Sydney, Australia; UNSW, Australia; Prince Wales & Royal Hosp Women, Australia (author)
  • Joly, FlorenceGrp Investigateurs Nationaux Etud Canc Ovariens GI, France; Ctr Francois Baclesse, France (author)
  • Hilpert, FelixArbeitsgesmeinschaft Gynakol Onkol Studiengrp AGO, Germany; North Eastern German Soc Gynecol Oncol NOGGO, Germany; Krankenhaus Jerusalem, Germany (author)
  • Lanceley, AnneUCL, England (author)
  • Yoshida, YoshioUniv Fukui, Japan (author)
  • Bryce, JaneMultictr Italian Trials Ovarian Canc & Gynecol Mal, Italy; Ascens St John Clin Res Inst, OK USA; Ist Nazl Tumori IRCCS Fdn Pascale, Italy (author)
  • Donnellan, PaulGalway Univ Hosp, Ireland (author)
  • Oza, AmitUniv Toronto, Canada (author)
  • Åvall Lundqvist, ElisabethLinköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Nord Soc Gynaecol Oncol NSGO, Denmark; Karolinska Inst, Sweden(Swepub:liu)eliav51 (author)
  • Berek, Jonathan S.Cooperat Gynecol Oncol Investigators COGI, CA USA; Stanford Univ, CA USA (author)
  • Ledermann, Jonathan A.Canc Res UK, England; UCL Canc Trials Ctr, England (author)
  • Berton, DominiqueGrp Investigateurs Nationaux Etud Canc Ovariens GI, France; Inst Cancerol Ouest, France (author)
  • Sehouli, JalidArbeitsgesmeinschaft Gynakol Onkol Studiengrp AGO, Germany; North Eastern German Soc Gynecol Oncol NOGGO, Germany; Charite Univ Med Berlin, Germany (author)
  • Kaminsky, Marie-ChristineGrp Investigateurs Nationaux Etud Canc Ovariens GI, France; Inst Cancerol Lorraine, France (author)
  • Stockler, Martin R.Univ Sydney, Australia (author)
  • Friedlander, MichaelUNSW, Australia; Prince Wales & Royal Hosp Women, Australia (author)
  • Univ Sydney, Australia; Western Sydney Univ, Australia; Campbelltown Hosp, AustraliaUniv Sydney, Australia (creator_code:org_t)

Related titles

  • In:Gynecologic Oncology: ACADEMIC PRESS INC ELSEVIER SCIENCE185, s. 128-1370090-82581095-6859

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view